Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms, The surveillance schedule, and the evidence that routine scans do not find relapse first, Low antibodies and infection risk for years after anti-CD20 and bispecific antibodies, Central venous access (port, PICC line) and the tag subtype-page.
Shares WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms, CD30 expression (CD30-positive), Central venous access (port, PICC line), Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy and the tag subtype-page.
Shares WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms, Deauville score and PET-adapted therapy, R-CHOP (lymphoma chemoimmunotherapy), Cytogenetics and FISH and the tag subtype-page.
Shares Tumour lysis syndrome (TLS), Autologous stem cell transplant (ASCT), Autologous stem cell transplant (high-dose therapy), Cyclophosphamide and the tag subtype-page.
Shares Tumour lysis syndrome (TLS), Cytogenetics and FISH, CD20, Rituximab and the tag subtype-page.
Shares Early integrated palliative care, Doxorubicin, IMRT / IGRT (modern external beam), Pembrolizumab and the tag subtype-page.
Shares Lisocabtagene maraleucel, CD20, CD19, Rituximab and the tag subtype-page.
Shares Nivolumab, PD-1, IMRT / IGRT (modern external beam), Pembrolizumab and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.